HK Stock Market Move | CF PHARMTECH (02652) rose nearly 3% in the morning. The company's minimally invasive intervention devices for the treatment of emphysema have completed their first trial entry.

CF PHARMTECH (02652) rose nearly 3% in the morning, as of the press release, it rose by 2.74%, to 29.2 Hong Kong dollars, with a turnover of 5.3645 million Hong Kong dollars. On the news front, according to CF PHARMTECH's official WeChat account, recently, CF PHARMTECH's independently developed bronchial valve lung volume reduction device successfully completed the first subject into the trial group (FPI). This clinical validation stage has officially begun, aiming to expand a minimally invasive intervention treatment path for patients with chronic obstructive pulmonary disease (COPD) such as emphysema. The successful completion of the first subject into the trial group marks the official entry of this innovative minimally invasive device into the clinical validation stage. It is reported that patients with emphysema often have dynamic over-inflation and limited activity, and there are many unmet clinical needs in effective long-term management and significant improvement in quality of life. This human experiment device relies on bronchoscopic branch-level airflow regulation and target lung volume reduction strategy, aiming to improve lung function and exercise tolerance while reducing residual volume (RV), as well as enhancing repeatability and postoperative manageability based on individualized assessment. This study will continue to enroll subjects according to the protocol, with perioperative safety monitoring and multidimensional evaluation of imaging/lung function. The main indicators cover device and operation-related safety, technical success rates, etc., and observe changes in key clinical outcomes such as FEV1, RV, 6MWD, and SGRQ; the research data will form an auditable evidence chain for subsequent registration strategies and commercial decisions.